

PSYCHEMEDICS CORP
Form 10-Q
October 27, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2016

or

Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
for the transition period from _____ to _____

Commission file number: 1-13738

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware **58-1701987**
(State or Other Jurisdiction of **(I.R.S. Employer Identification No.)**
Incorporation or Organization)

125 Nagog Park
Acton, MA **01720**
(Address of Principal Executive Offices) **(Zip Code)**

Registrant's telephone number including area code: (978) 206-8220

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

Large accelerated filer Accelerated filer Non-accelerated filer Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes No

The number of shares of Common Stock of the Registrant, par value \$0.005 per share, outstanding at October 25, 2016 was 5,460,220.

PSYCHEMEDICS CORPORATION

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2016

INDEX

	Page
PART I - FINANCIAL INFORMATION	
Item 1 - Financial Statements (Unaudited)	
<u>Condensed Balance Sheets as of September 30, 2016 and December 31, 2015</u>	3
<u>Condensed Statements of Income for the Three and Nine Months ended September 30, 2016 and 2015</u>	4
<u>Condensed Statements of Cash Flows for the Nine Months ended September 30, 2016 and 2015</u>	5
<u>Notes to Condensed Financial Statements</u>	6
<u>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	11
<u>Overview</u>	12
<u>Results of Operations</u>	12
<u>Liquidity and Capital Resources</u>	14
<u>Item 3 - Quantitative and Qualitative Disclosures About Market Risk</u>	15
<u>Item 4 - Controls and Procedures</u>	15
<u>PART II - OTHER INFORMATION</u>	16
<u>Item 1A - Risk Factors</u>	16
<u>Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds</u>	16
<u>Item 6 - Exhibits</u>	16
<u>Signatures</u>	16
<u>Exhibit Index</u>	17

PSYCHEMEDICS CORPORATION**CONDENSED BALANCE SHEETS****(UNAUDITED)**

	September 30, 2016	December 31, 2015
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 4,111,808	\$ 2,689,464
Accounts receivable, net of allowance for doubtful accounts of \$55,743 in 2016 and \$58,684 in 2015	6,272,108	3,538,765
Prepaid expenses and other current assets	1,266,409	1,060,587
Income tax receivable	-	840,122
Deferred tax assets	536,097	327,442
Total Current Assets	12,186,422	8,456,380
Fixed Assets, net of accumulated amortization and depreciation of \$8,240,883 in 2016 and \$6,642,501 in 2015	12,926,146	13,132,114
Other assets	815,987	774,474
Total Assets	\$ 25,928,555	\$ 22,362,968
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable	\$ 1,144,236	\$ 747,291
Accrued expenses	1,587,584	1,197,632
Accrued income taxes	1,024,102	-
Current portion of long-term debt	1,741,602	1,619,633
Total Current Liabilities	5,497,524	3,564,556
Long-term debt	3,484,303	4,272,137
Deferred tax liabilities, long-term	3,043,911	2,852,745
Total Liabilities	12,025,738	10,689,438
Commitments and Contingencies (Note 7)		
Shareholders' Equity:		
Preferred-stock, \$0.005 par value, 872,521 shares authorized, no shares issued or outstanding	-	-
Common stock, \$0.005 par value; 50,000,000 shares authorized 6,128,350 shares issued in 2016 and 6,090,671 shares issued in 2015	30,642	30,453
Additional paid-in capital	30,439,974	30,021,604

Edgar Filing: PSYCHEMEDICS CORP - Form 10-Q

Accumulated deficit	(6,486,010)	(8,296,738)
Less - Treasury stock, at cost, 668,130 shares	(10,081,789)	(10,081,789)
Total Shareholders' Equity	13,902,817	11,673,530
Total Liabilities and Shareholders' Equity	\$ 25,928,555	\$ 22,362,968

See accompanying notes to condensed financial statements

PSYCHEMEDICS CORPORATION**CONDENSED STATEMENTS OF INCOME****(UNAUDITED)**

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2016	2015	2016	2015
Revenues	\$11,849,163	\$7,084,265	\$28,216,279	\$20,841,415
Cost of revenues	4,744,273	3,627,582	13,163,802	10,776,122
Gross profit	7,104,890	3,456,683	15,052,477	10,065,293
Operating Expenses:				
General & administrative	1,277,988	1,229,441	3,715,838	3,528,020
Marketing & selling	1,374,896	1,284,016	3,804,584	3,894,614
Research & development	347,970	392,042	1,058,633	1,284,914
Total Operating Expenses	3,000,854	2,905,499	8,579,055	8,707,548
Operating income	4,104,036	551,184	6,473,422	1,357,745
Interest expense, net	(33,904)	(30,411)	(104,037)	(94,614)
Net income before income taxes	4,070,132	520,773	6,369,385	1,263,131
Provision for (benefit from) income taxes	1,362,111	(275,612)	2,051,053	(63,106)
Net income	\$2,708,021	\$796,385	\$4,318,332	\$1,326,237
Basic net income per share	\$0.50	\$0.15	\$0.79	\$0.25
Diluted net income per share	\$0.49	\$0.15	\$0.79	\$0.25
Dividends declared per share	\$0.15	\$0.15	\$0.45	\$0.45
Weighted average common shares outstanding, basic	5,459,802	5,422,541	5,441,967	5,399,131
Weighted average common shares outstanding, diluted	5,510,042	5,424,989	5,457,368	5,406,053

See accompanying notes to condensed financial statements

PSYCHEMEDICS CORPORATION**CONDENSED STATEMENTS OF CASH FLOWS****(UNAUDITED)**

	Nine Months Ended September 30,	
	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$4,318,332	\$1,326,237
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,625,979	1,102,112
Change in excess tax benefit related to stock	—	86,433
Stock-based compensation	507,888	514,422
Changes in assets and liabilities:		
Accounts receivable	(2,733,343)	(1,375,031)
Prepaid expenses, other current assets, and income tax receivable	634,300	787,769
Accounts payable	321,524	(209,627)
Accrued expenses and accrued income taxes	1,414,054	43,335
Deferred income taxes	(17,489)	(225,138)
Net cash provided by operating activities	6,071,245	2,050,512
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of equipment and leasehold improvements	(1,181,244)	(1,091,683)
Cost of internally developed software	(135,749)	(310,981)
Other assets	(69,110)	(23,011)
Net cash used in investing activities	(1,386,103)	(1,425,675)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net proceeds from exercise of stock options	-	91,556
Proceeds from issuance of stock, net of tax withholding	(148,829)	(226,608)
Proceeds from equipment financing	609,844	1,098,539
Payments of equipment financing	(1,275,709)	(1,049,944)
Cash dividends paid	(2,448,104)	(2,428,639)
Net cash used in financing activities	(3,262,798)	(2,515,096)
Net increase (decrease) in cash and cash equivalents	1,422,344	(1,890,259)
Cash and cash equivalents, beginning of period	2,689,464	3,612,153
Cash and cash equivalents, end of period	\$4,111,808	\$1,721,894

Supplemental Disclosures of Cash Flow Information:

Edgar Filing: PSYCHEMEDICS CORP - Form 10-Q

Cash paid for income taxes	\$921,078	\$2,870
Cash paid for interest	\$104,710	\$94,385
Purchases of equipment through accrued liabilities	\$75,421	\$5,037

See accompanying notes to condensed financial statements

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

1. Interim Financial Statements

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the financial statements and related notes of Psychemedics Corporation (“the Company,” “our Company,” “our” or “we”) as reported in the Company’s Annual Report on Form 10-K (“10-K”) for the year ended December 31, 2015, filed on February 26, 2016. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented have been included. The results of operations for the three and nine months ended September 30, 2016 may not be indicative of the results that may be expected for the year ending December 31, 2016, or any other period.

2. Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consisted exclusively of cash in the bank as of December 31, 2015 and September 30, 2016.

3. Stock-Based Compensation

The Company’s 2006 Incentive Plan (“the Plan”) provides for cash based awards or the grant or issuance of stock-based awards including; options, restricted stock or stock unit awards (SUA’s).

Activity for SUAs under the Plan for the nine months ended September 30, 2016 was as follows:

Aggregate

	Number of Shares	Intrinsic Value (1) (000s)
Unvested, December 31, 2015	111,464	
Granted	16,600	
Forfeited/expired	(16,760)	
Converted to common stock	(37,679)	
Unvested, September 30, 2016	73,625	\$ 1,462

1) The aggregate intrinsic value on these tables was calculated based on the closing market value of the Company's stock on September 30, 2016 (\$19.82).

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

3. Stock-Based Compensation (continued)

Activity for options under the Plan for the nine months ended September 30, 2016 was as follows:

	Number of Shares	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value (2) (000s)
Outstanding, December 31, 2015	47,000	\$ 10.21		
Granted	120,500	\$ 13.82		
Exercised	-	-		
Terminated/Expired	(7,500)	\$ 13.82		
Outstanding, September 30, 2016	160,000	\$ 12.76	9.4 years	\$ 1,130
Exercisable, September 30, 2016	9,400	\$ 10.21	9.0 years	\$ 91

The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market (2) value of the Company's stock on the September 30, 2016 (\$19.82) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.

As of September 30, 2016, a total of 541,017 shares of common stock were reserved for issuance under the 2006 Incentive Plan. As of September 30, 2016, the unamortized fair value of awards relating to outstanding SUAs and options was \$1.1 million, which is expected to be amortized over a weighted average period of 2.8 years. The total number of shares available for grant as of September 30, 2016 was 307,392.

PSYCHEMEDICS CORPORATION**NOTES TO CONDENSED FINANCIAL STATEMENTS****(UNAUDITED)****4. Basic and Diluted Net Income Per Share**

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period is determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the three and nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Weighted average common shares outstanding, basic	5,460	5,423	5,442	5,399
Dilutive common equivalent shares	50	2	15	7
Weighted average common shares outstanding, diluted	5,510	5,425	5,457	5,406

5. Fair Value Measurements

The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company's long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the company.

6. Subsequent Events

On October 26, 2016, the Company declared a quarterly dividend of \$0.15 per share for a total of \$819 thousand, which will be paid on November 17, 2016 to shareholders of record on November 7, 2016.

7. Commitments and Contingencies

The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. The Company believes that based upon information available to the Company at this time, the expected outcome of these matters would not have a material impact on the Company's results of operations or financial condition.

PSYCHEMEDICS CORPORATION**NOTES TO CONDENSED FINANCIAL STATEMENTS****(UNAUDITED)****8. Debt and Other Financing Arrangements**

On March 20, 2014, the Company entered into an equipment financing arrangement (“Loan Arrangement”) with Banc of America Leasing & Capital, LLC, which it amended on September 15, 2015. The terms of this arrangement are detailed in the 10-K.

On March 23, 2016, under the Loan Arrangement, the Company executed a note in the amount of \$609 thousand, for total borrowings of \$8.7 million. The weighted average interest rate for all notes related to the Loan Arrangement for the quarter ended September 30, 2016 was 2.5%, and represented \$33,904 of interest expense as compared to a rate of 2.2% and interest expense of \$30,411 for the comparable period in 2015. The weighted average interest rate for all notes related to the Loan Arrangement for the nine months ended September 30, 2016 was 2.4%, and represented \$104,037 of interest expense as compared to a rate of 2.2% and interest expense of \$94,614 for the comparable period in 2015. As of September 30, 2016, the interest rate was 2.5% and there was \$5.2 million of outstanding debt related to the loan. The Company was in compliance with all loan covenants as of September 30, 2016.

The annual principal repayment requirements for debt obligations as of September 30, 2016 were as follows (in 000’s):

2016	\$435
2017	1,742
2018	1,742
2019	990
2020	287
2021	30
Total long-term debt	5,226
Less current portion of long-term debt	(1,742)
Total long-term debt, net of current portion	\$3,484

9. Significant Customers

Edgar Filing: PSYCHEMEDICS CORP - Form 10-Q

The Company had one customer that exceeded 10% of revenue for the three and nine months ended September 30, 2016. There were no customers that exceeded 10% of revenue for the same periods in 2015. The Company had one customer that accounted for 29% and 9% of the total accounts receivable balance as of September 30, 2016 and December 31, 2015, respectively.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

10. Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases, which introduces the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. The new standard will become effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. The new standard will become effective beginning with the first quarter of 2017, with early adoption permitted. The Company elected early adoption of ASU 2016-09 in the second quarter of 2016 which will be applied using a modified retrospective approach. The adoption of ASU 2016-09 did not materially impact the Company's financial position, results of operations, equity or cash flows. As a result of our adoption of ASU 2016-09, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable. Additionally, we recognize the cash flow impact of such excess tax benefits in operating activities in our condensed statements of cash flows. The cumulative impact upon adoption was a \$41 thousand benefit from income taxes and a \$60 thousand adjustment to retained earnings.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FACTORS THAT MAY AFFECT FUTURE RESULTS

From time to time, information provided by the Company or statements made by its employees may contain "forward-looking" information which involves risks and uncertainties. In particular, statements contained in this report which are not historical facts (including, but not limited to, the Company's expectations regarding earnings, earnings per share, revenues, operating cash flows, profitability, margins, pricing, dividends, future business, growth opportunities, new accounts, customer base, test volume, sales and marketing strategy, business strategy, general and administrative expenses, marketing and selling expenses, research and development expenses, anticipated operating results, foreign drug testing laws and regulations and the enforcement of such laws and regulations, required investments in plant, property and equipment, strategies with respect to governmental agencies and regulations, cost savings, capital expenditures, liquidity of investments and anticipated cash requirements) may be "forward-looking" statements. The Company's actual results may differ from those stated in any "forward-looking" statements. Factors that may cause such differences include, but are not limited to, risks associated with employee hiring practices of the Company's principal customers, development of markets for new products and services offered by the Company, costs associated with capacity expansion, government regulation (including, but not limited to, Food and Drug Administration regulations and foreign government regulation including Brazilian commercial drivers license drug test law and regulations), risks associated with the delay in the implementation of new regulations, competition and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, available surplus, cash flow, capital expenditure reserves required, debt service obligations, and other factors that the Board of Directors of the Company may take into account.

Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements represent the Company's estimates and assumptions only as of the filing date of this Report. The Company expressly disclaim any duty to provide updates to forward-looking statements, and the estimates and assumptions associated with them, after the filing date of this Report, in order to reflect changes in circumstances or expectations, or the occurrence of unanticipated events, except to the extent required by applicable securities laws. All of the forward-looking statements are qualified in their entirety by reference to the factors discussed above and under "Risk Factors" set forth in Part I Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as well as the risks and uncertainties discussed elsewhere in this Report. The Company qualifies all of its forward-looking statements by these cautionary statements. The Company cautions you that these risks are not exhaustive. The Company operates in a continually changing business environment and new risks emerge from time to time.

OVERVIEW

Revenues for the third quarter of 2016 were \$11.8 million, an increase of 67% from third quarter 2015 revenue of \$7.1 million. The Company reported net income of \$2.7 million, or \$0.49 per diluted share for the three months ended September 30, 2016 versus \$796 thousand, or \$0.15 per diluted share for the same period in 2015, an increase of 240%. The increase in revenue and earnings was primarily the result of higher testing volume from Brazil. The Brazil opportunity derived from the implementation of a recently passed Brazilian law requiring a hair drug test for all professional drivers in the country that began to take effect in March 2016. The Company distributed \$2.5 million or \$0.45 per share of cash dividends to its shareholders in the nine months ended September 30, 2016. The Company has paid 80 consecutive quarterly cash dividends.

RESULTS OF OPERATIONS

Revenues were \$11.8 million for three months ended September 30, 2016 compared to revenues of \$7.1 million for the three months ended September 30, 2015, representing an increase of 67%. The increase was attributable to testing volume from Brazil. Revenues for the nine months ended September 30, 2016 were \$28.2 million, representing an increase of 35% in revenues from the comparable period of 2015 of \$20.8 million. This increase was primarily attributable to testing volume from Brazil.

Gross profit was \$7.1 million for the three months ended September 30, 2016, compared to \$3.5 million for the same period in 2015, representing an increase of 106%. Direct costs increased by \$1.1 million or 31% for the three months ended September 30, 2016 compared to the same period in 2015, mainly due to the higher volume of samples. As a result of the higher sales, the gross profit margin increased to 60% for the three months ended September 30, 2016 from 49% for the comparable period of 2015. Gross profit for the nine months ended September 30, 2016 increased \$5.0 million to \$15.1 million. Direct costs increased by \$2.4 million or 22% for the nine months ended September 30, 2016 compared to the same period in 2015, mainly due to the higher volume of samples. As a result of the higher sales, the gross profit margin increased to 53% for the nine months ended September 30, 2016 from 48% for the comparable period of 2015.

General and administrative (“G&A”) expenses were \$1.3 million for the three months ended September 30, 2016, compared to \$1.2 million for the same period in 2015. As a percentage of revenue, G&A expenses were 11% for the three months ended September 30, 2016, compared to 17% for the same period in 2015. General and administrative expenses were \$3.7 million for the nine months ended September 30, 2016, compared to \$3.5 million for the same period in 2015. As a percentage of revenue, G&A expenses were 13% for the nine months ended September 30, 2016, compared to 17% for the same period in 2015.

Marketing and selling expenses were \$1.4 million for the three months ended September 30, 2016, compared to \$1.3 million for the same period in 2015. Total marketing and selling expenses represented 12% of revenue for the three months ended September 30, 2016, compared to 18% for the same period in 2015. Marketing and selling expenses were \$3.8 million for the nine months ended September 30, 2016, compared to \$3.9 million for the nine months ended September 30, 2015. Total marketing and selling expenses represented 13% of revenue for the nine months ended September 30, 2016, compared to 19% for the comparable period of 2015.

Research and development (“R&D”) expenses for the three months ended September 30, 2016 were \$348 thousand compared to \$392 thousand for the comparable period of 2015, a decrease of 11%. R&D expenses represented 3% and 6% of revenue for the three months ended September 30, 2016 and 2015, respectively. Research and development expenses for the nine months ended September 30, 2016 were \$1.1 million compared to \$1.3 million in the prior year, a decrease of 18%. R&D expenses represented 4% and 6% of revenue for the nine months ended 2016 and 2015, respectively.

Provision for income taxes During the three months ended September 30, 2016 the Company recorded a provision of \$1.4 million. For the three months ended September 30, 2015, the Company recorded a benefit of \$276 thousand which consisted of a 2015 tax provision of \$203 thousand, offset by \$479 thousand of R&D tax credits. The respective provision and benefit represented effective tax rates of 33% for the three months ended September 30, 2016 and (53%) for the comparable period of 2015. During the nine months ended September 30, 2016, the Company recorded a provision of \$2.1 million. For the nine months ended September 30, 2015, the Company recorded a benefit of \$63 thousand, due to R&D tax credits. The respective provision and benefit represented effective tax rates of 32% for the nine month periods ended September 30, 2016 and (5%) for the comparative period last year. The Company expects the year-end tax rate to be between 32% and 34%.

LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2016, the Company had approximately \$4.1 million of cash. The Company's operating activities generated net cash of \$6.1 million for the nine months ended September 30, 2016. Investing activities used \$1.4 million of cash while financing activities used \$3.3 million of cash during the first nine months of 2016.

Cash provided by operating activities of \$6.1 million reflected net income of \$4.3 million adjusted for depreciation and amortization of \$1.6 million and stock-based compensation of \$508 thousand. This was affected by the following changes in assets and liabilities: an increase in accounts receivable of \$2.7 million, a decrease in prepaid expenses, other current assets and income tax receivable of \$634 thousand, an increase in accounts payable of \$397 thousand, an increase in accrued expenses of \$1.3 million and a decrease in deferred income taxes of \$17 thousand. The increase in accrued expenses was driven a \$1.0 million increase in accrued income taxes.

Cash used in investing activities primarily included equipment and leasehold improvements of \$1.2 million which were purchased during the first nine months of 2016. We anticipate spending \$0.5 million to \$1.0 million in additional capital purchases for the remainder of 2016.

Cash used by financing activities of \$3.3 million primarily included cash dividends to shareholders of \$2.5 million and \$1.3 million from payments on long term debt, offset by \$610 thousand of proceeds from additional equipment financing. On October 25, 2016, the Company declared a quarterly dividend of \$0.15 per share for an estimated total of \$819 thousand, which will be paid on November 14, 2016 to shareholders of record on November 4, 2016.

Contractual obligations and other commercial commitments as of September 30, 2016 were as follows (in thousands):

	Less Than One Year	1-3 Years	4-5 Years	After 5 Years	Total
Debt principal	\$ 1,742	\$3,082	\$ 402	\$ -	\$5,226
Operating leases	923	1,487	462	-	2,872
Total	\$ 2,665	\$4,569	\$ 864	\$ -	\$8,098

At September 30, 2016, the Company's principal source of liquidity consisted of approximately \$4.1 million of cash. Management currently believes that such funds, together with cash generated from operations, should be adequate to fund anticipated working capital requirements and capital equipment expenditures for the next 12 months. Depending upon the Company's results of operations and capital needs, the Company may use various financing sources to raise

additional funds.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity. The Company's long-term debt agreement is subject to the 30 day Libor rate, which changes the Company's interest rate on a monthly basis. The Company does not expect any changes in this rate to materially affect the Company's performance.

Based on our ability to access our cash and cash equivalents, our expected operating cash flows and our other sources of cash, we do not anticipate that any lack of liquidity will materially affect our ability to operate our business.

Item 4. Controls and Procedures

As of the end of the period covered by this report, the Company's management under the supervision and with the participation of, the Company's Chief Executive Officer and Vice President – Finance, performed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the Chief Executive Officer and Vice President - Finance concluded that the Company's disclosure controls and procedures were effective for ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that its disclosure controls and procedures were also effective to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the Company's principal executive and principal financial officers, to allow timely decisions regarding required disclosure.

There has been no significant change in the Company's internal control over financial reporting during the most recent fiscal quarter that has materially affected or is reasonably likely to materially affect the Company's internal control over financial reporting.

PART II OTHER INFORMATION

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our 2015 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no purchases of treasury stock in the first nine months of 2016.

Item 6. Exhibits

See Exhibit Index included in this Report

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Psychemedics Corporation

Date: October 27, 2016 By: /s/ Raymond C. Kubacki
Raymond C. Kubacki
Chairman and Chief
Executive Officer
(principal executive officer)

Date: October 27, 2016 By: /s/ Neil L. Lerner

Neil L. Lerner
Vice President - Finance
(principal accounting officer)

PSYCHEMEDICS CORPORATION

FORM 10-Q

September 30, 2016

EXHIBIT INDEX

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema

101.CAL XBRL Taxonomy Extension Calculation Linkbase

101.LAB XBRL Taxonomy Extension Label Linkbase

101.PRE XBRL Taxonomy Extension Presentation Linkbase

101.DEF XBRL Taxonomy Extension Definition Linkbase